Trial Profile
DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms DETERRED
- 16 Jan 2024 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
- 16 Jan 2024 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.
- 11 Jan 2024 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.